Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio.

Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.

SynAct Pharma has formalised a Brazilian partnership with Hipolabor to develop and commercialise investigational resomelagon for dengue treatment under a 50-50 cost and profit-sharing structure.